H-1B Visa: US Govt Allows Fast Processing For Some Applications

Agencies
July 25, 2017

Washington, Jul 25: The US government said on Monday it would resume fast processing of H-1B visas requested by institutions of higher education and nonprofit and governmental research organisations, while leaving in place a longer approval time for companies that use the visas.Visa

US President Donald Trump campaigned on a promise to crack down on immigrants, whom he said were taking jobs from US citizens, and signed an executive order in April calling for a review of the H-1B program. The visa allows foreigners with certain skills to work temporarily in the United States.

US companies often use the visas to hire graduate-level workers in several specialised fields, including information technology, medicine, engineering and mathematics. The visas are heavily used in the tech sector.

On April 3, the US Citizenship and Immigration Services (USCIS) suspended "premium processing" of the visas for up to six months. Under the expedited procedure, applicants can be eligible for visa approvals within 15 days, instead of a regular review period that can last several months.

The United States currently caps H-1B visas at 65,000 a year, with an additional 20,000 allowed for those who have earned advanced college degrees in the United States.

The overall suspension remains in place but USCIS said on Monday in a statement that premium processing would resume for some applications from educational and research-oriented organisations exempt from the cap.

The agency resumed premium processing for physicians working under a specific waiver program on June 26.

The USCIS has said that suspending premium processing was necessary to reduce a backlog of long-pending visa petitions and thus reduce overall H-1B processing times.

Comments

Jon
 - 
Saturday, 29 Jul 2017

It is really great news for indian IT folks

Moorthi
 - 
Thursday, 27 Jul 2017

it is good news for Indian IT employees to switch the job easily here.

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 22,2020

Karachi, Jun 22: India-born renowned Pakistani Shia scholar and author Talib Jauhari passed away here after a prolonged illness. He was 80.

Jauhari, who was born on August 27, 1939 in Patna, is survived by his three sons, Dawn News reported on Monday.

He migrated to Pakistan along with his father in 1949, two years after the Partition.

After obtaining early education from his father, he went to Iraq where he studied religion for 10 years under the renowned Shia scholars of that time.

Jauhari, who was on a ventilator in the intensive care unit of a private hospital for the past 15 days, breathed his last on Sunday night.

His son Riaz Jauhari confirmed his death and said that the body has been shifted to Ancholi Imambargah for the funeral prayers, The Express Tribune newspaper quoted his son as saying.

Jauhari was respected among his sect as he was a class fellow of the widely revered scholar Ayatollah Sayyid Ali al-Husayni al-Sistani.

He was also a poet, historian and philosopher and authored many books.

Pakistan Prime Minister Imran Khan has condoled Jauhari's death.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 29,2020

Karachi, Jun 29: Four heavily-armed militants attacked the busy Pakistan Stock Exchange on Monday morning, killing four security guards and a police sub-inspector before being shot dead in an exchange of fire, media reports said.

The unidentified militants opened indiscriminate fire and lobbed hand grenades at the main gate of the building as they tried to storm it, Geo News reported.

Police said that all the terrorists have been killed while five persons injured in the attack.

Four security guards and a police sub-inspector were also killed in the attack.

"An unfortunate incident took place at the Pakistan Stock Exchange. They made their way from our parking area and opened fire on everyone," said Abid Ali Habib, Director of Pakistan Stock Exchange.

The firing by militants caused panic among the people in the building.

Sindh province Governor Imran Ismail condemned the incident.

"Strongly condemn the attack on PSX aimed at tarnishing our relentless war on terror. Have instructed the IG & security agencies to ensure that the perpetrators are caught alive & their handlers are accorded exemplary punishments. We shall protect Sindh at all costs," he said on Twitter.

Police and rangers have arrived on the spot and surrounded the area.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.